Antiviral Drugs - Netherlands

Netherlands

In the Netherlands, the projected revenue in the Antiviral Drugs market for 2024 is expected to reach €214.40m.
Looking ahead, the market is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 1.85%, ultimately leading to a market volume of €235.00m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Antiviral Drugs market, with an estimated value of €28,420.00m in 2024.
The Netherlands has a robust market for antiviral drugs, with a focus on research and development of innovative therapies.

Key regions: Brazil, India, Australia, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Antiviral Drugs market in Netherlands is experiencing steady growth due to various factors.

Customer preferences: Customers in the Netherlands are increasingly becoming aware of the importance of antiviral drugs in treating viral infections. The rising prevalence of viral infections such as HIV, hepatitis, and influenza has led to an increase in demand for antiviral drugs. Additionally, the aging population in the country is also contributing to the growth of the market.

Trends in the market: The antiviral drugs market in the Netherlands is witnessing a shift towards the development of new and innovative drugs. This is due to the rising prevalence of drug-resistant viruses and the need for more effective treatments. There is also an increasing trend towards the use of combination therapies, which involve the use of two or more drugs to treat viral infections. This approach has been found to be more effective in treating viral infections than using a single drug.

Local special circumstances: The Netherlands has a well-developed healthcare system that provides universal coverage to its citizens. This has led to increased access to antiviral drugs for patients in the country. Additionally, the country has a strong pharmaceutical industry, which is contributing to the development of new antiviral drugs.

Underlying macroeconomic factors: The Netherlands has a stable economy, which is contributing to the growth of the antiviral drugs market. The country has a high standard of living and a well-educated population, which is driving demand for innovative treatments. Additionally, the government in the Netherlands has implemented policies to promote the development of the pharmaceutical industry in the country. This has led to increased investment in research and development, which is contributing to the growth of the antiviral drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.